Compare LADR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LADR | TRVI |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2013 | 2019 |
| Metric | LADR | TRVI |
|---|---|---|
| Price | $10.35 | $13.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $12.25 | ★ $21.55 |
| AVG Volume (30 Days) | 992.2K | ★ 1.7M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 8.98% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.66 | N/A |
| Revenue Next Year | $16.92 | N/A |
| P/E Ratio | $515.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.61 | $5.38 |
| 52 Week High | $11.92 | $16.12 |
| Indicator | LADR | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 55.12 |
| Support Level | $10.16 | $10.07 |
| Resistance Level | $10.54 | $13.97 |
| Average True Range (ATR) | 0.17 | 0.87 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 59.72 | 24.92 |
Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments: Loans, which derive maximum revenue; Securities; and Real Estate.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.